Alice Melão,  —

Denali Therapeutics has begun dosing patients in its Phase 1b clinical trial of DNL747 as a treatment for Alzheimer’s disease. “We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS [central nervous system] penetration, and target engagement, at the studied doses,”…

Inhibiting a protein called NHE6 is a potential strategy to prevent the damaging effect of ApoE4 and the associated risk of late-onset Alzheimer’s disease, a study suggests. The study, “Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease,” was led by University of…

Extracts from three South African plants can help prevent the formation of toxic amyloid protein aggregates known to contribute to the progression of Alzheimer’s disease, a research study revealed. This finding may help identify new active compounds to be explored as potential therapeutic strategies for Alzheimer’s. The study, “…

CavoGene LifeSciences is going to explore a new gene therapy, called SynCav1, that may represent an alternative and attractive strategy to treat several neurodegenerative diseases, including Alzheimer’s. This follows CavoGene’s acquisition of SynCav1’s developmental and commercialization rights from the University of California San Diego. SynCav1 was designed to specifically…

Commonly used antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, can prevent beta-amyloid aggregation, representing a potential new therapeutic strategy for Alzheimer’s disease, a study suggests. The study, “Interactions of Selective Serotonin Reuptake Inhibitors with β-Amyloid,” was published in ACS Chemical Neuroscience.

A newly developed antibody targeting a protein called fibrin was seen to prevent inflammation and oxidative stress induced by amyloid aggregates in the brains of a mouse model of Alzheimer’s disease. These findings may pave the way for a new way of treating and preventing the neurodegeneration associated with Alzheimer’s…

Fasudil, a chemical inhibitor used to treat strokes, may prevent early nerve cell impairment and sustainment of beta-amyloid damaging effects, opening new therapeutic avenues for Alzheimer’s disease, according to a mouse study. These findings could not only help researchers understand the mechanisms behind Alzheimer’s development and progression, but also may shed light…

An investigational antibody effectively targeted toxic protein aggregation in the brain of a mouse model of Alzheimer’s disease, improving memory and cognitive functions in the animals. University of the Witwatersrand researchers are now planning Phase 1 of human clinical trials with 30 to 50 volunteers who have Alzheimer’s. If the results are positive, the team hopes…

The absolute 10-year risk of dementia varies according to age, gender, and common variation in the APOE gene, according to a large-scale Danish study. This discovery may help identify high-risk individuals who may benefit from early targeted intervention to prevent dementia’s development and progression. The study, “Absolute…

Flortaucipir, an investigational imaging agent, was able to efficiently detect Tau protein aggregates and related Alzheimer’s disease brain changes, meeting both of its primary objectives in a Phase 3 trial. Results of the trial revealed that flortaucipir demonstrated great sensitivity in identifying tau-related damage and predicting Alzheimer’s disease diagnosis.